| 张英楠,傅永艳,任 红,刘 畅,张更华.雷珠单抗联合视网膜激光光凝术对BRVO继发黄斑水肿患者视网膜电图P1波及生活质量的影响[J].,2021,(2):264-268 |
| 雷珠单抗联合视网膜激光光凝术对BRVO继发黄斑水肿患者视网膜电图P1波及生活质量的影响 |
| The Effect of Laser Photocoagulation Combined with Ranibizumab on Electroretinogram P1 and Quality of Life in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion |
| 投稿时间：2020-04-27 修订日期：2020-05-21 |
| DOI：10.13241/j.cnki.pmb.2021.02.014 |
| 中文关键词: 雷珠单抗 视网膜激光光凝术 视网膜分支静脉阻塞 黄斑水肿 视网膜电图P1波 生活质量 |
| 英文关键词: Ranibizumab Retinal laser photocoagulation Branch retinal vein occlusion Macular edema P1 wave of electroretinogram Quality of life |
| 基金项目:辽宁省科学技术计划项目（2017-ZD-0719） |
|
| 摘要点击次数: 767 |
| 全文下载次数: 636 |
| 中文摘要: |
| 摘要 目的：探讨雷珠单抗联合视网膜激光光凝术对视网膜分支静脉阻塞（BRVO）继发黄斑水肿患者视网膜电图P1波及生活质量的影响。方法：选取2017年1月~2019年8月期间我院收治的BRVO继发黄斑水肿患者60例，根据随机数字表法分为对照组（n=30）和研究组（n=30），对照组患者予以雷珠单抗治疗，研究组则在对照组的基础上联合视网膜激光光凝术治疗，比较两组患者疗效、视网膜电图P1波、生活质量及不良反应。结果：研究组治疗后6个月的临床总有效率为93.33%（28/30），高于对照组的70.00%（21/30）（P<0.05）。两组患者治疗后1个月、治疗后3个月、治疗后6个月健康调查简表（SF-36）评分均升高，且研究组高于对照组（P<0.05）。两组治疗后6个月视力升高，黄斑中心视网膜厚度（CMT）、眼压降低（P<0.05）；研究组治疗后6个月视力高于对照组，CMT、眼压低于对照组（P<0.05）。研究组治疗后6个月1环、2环、3环的P1波振幅密度高于对照组（P<0.05）；而1环、2环、3环的P1波潜伏期低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：BRVO继发黄斑水肿患者经视网膜激光光凝术联合雷珠单抗治疗后，疗效显著，可有效提高视力及生活质量，改善黄斑水肿及病变区域的视网膜功能，且不增加不良反应发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of laser photocoagulation combined with ranibizumab on the electroretinogram P1 and quality of life in patients with macular edema secondary to branch vein occlusion (BRVO). Methods: From January 2017 to August 2019, 60 patients with macular edema secondary to BRVO in our hospital were selected, they were divided into control group (n=30) and study group (n=30) according to the method of random number table. Patients in the control group were treated with ranibizumab, while those in the study group were treated with retinal laser photocoagulation on the basis of the control group. The efficacy, P1 wave of electroretinogram, quality of life and adverse reactions of the two groups were compared. Results: The total clinical effective rate of the study group was 93.33% (28/30), which was higher than 70.00% (21/30) of the control group (P<0.05). The scores of health survey summary (SF-36) of the two groups were increased at 1 month after treatment, 3 months after treatment and 6 months after treatment, and those of the study group were higher than those of the control group (P<0.05). 6 months after treatment, the visual acuity of the two groups increased, and macular central retinal thickness (CMT) and intraocular pressure decreased (P<0.05). The visual acuity of the study group at 6 months after treatment was higher than that of the control group, and CMT and intraocular pressure were lower than those of the control group (P<0.05). 6 months after treatment, the P1 wave amplitude density of the 1st, 2nd and 3rd rings in the study group were higher than those of the control group (P<0.05), while the P1 wave latency of the 1st, 2nd and 3rd rings were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Ranibizumab combined with retinal laser photocoagulation is effective in the treatment of macular edema secondary to BRVO, which can effectively improve vision and quality of life, improve macular edema, and do not increase the incidence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
